Form 8.5 (EPT/RI)-Dechra Pharmaceuticals plc

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

(a) Name of exempt principal trader:	Morgan Stanley & Co. International plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	Dechra Pharmaceuticals plc
(c) Name of the party to the offer with which exempt principal trader is connected:	EQT (EQT X EUR SCSp and EQT X USD SCSp)
(d) Date dealing undertaken:	13 November 2023
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A"	N/A

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	CFD	increasing a long position	364	37.7800 GBP
1p ordinary	CFD	increasing a long position	212	37.7800 GBP
1p ordinary	CFD	increasing a long position	939	37.7800 GBP
1p ordinary	CFD	increasing a long position	1,129	37.7800 GBP
1p ordinary	CFD	increasing a long position	380	37.7913 GBP
1p ordinary	CFD	increasing a long position	17	37.8153 GBP
1p ordinary	CFD	increasing a long position	692	37.8194 GBP
1p ordinary	CFD	increasing a long position	274	37.8228 GBP
1p ordinary	CFD	increasing a long position	203	37.8343 GBP
1p ordinary	CFD	increasing a long position	42	37.8487 GBP
1p ordinary	CFD	increasing a long position	799	37.8569 GBP
1p ordinary	CFD	increasing a short position	857	37.8191 GBP
1p ordinary	CFD	increasing a short position	1	37.8600 GBP
1p ordinary	CFD	increasing a short position	892	37.8600 GBP
1p ordinary	CFD	increasing a short position	135	37.8800 GBP
1p ordinary	CFD	increasing a short position	862	37.8800 GBP
1p ordinary	CFD	reducing a long position	380	37.7800 GBP
1p ordinary	CFD	reducing a long position	6	37.8467 GBP
1p ordinary	CFD	reducing a long position	28	37.8497 GBP
1p ordinary	CFD	reducing a long position	33	37.8497 GBP
1p ordinary	CFD	reducing a short position	1	37.7913 GBP
1p ordinary	CFD	reducing a short position	117	37.8601 GBP

Date of disclosure:	14 November 2023
Contact name:	Craig Horsley
Telephone number:	+44 141 245-7736

Date of disclosure:

Contact name:

Telephone number:

Companies

UK 100

Latest directors dealings